Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The RECOVERY Trial: how to save more than a million lives

trial registrations

The RECOVERY Trial is registered at ISRCTN50189673 
EU Clinical Trials Register: EudraCT 2020-001113-21
Clinical Trials.gov: NCT04381936

A range of promising but unproven treatments are being evaluated in RECOVERY. The treatments being tested depend on the cause of pneumonia:

For patients with pneumonia caused by COVID-19

  • sotrovimab (an antibody treatment against the spike protein)
  • high dose corticosteroids (an immune suppressant) in the sickest patients who need mechanical breathing support.

For patients with pneumonia caused by influenza

  • oseltamivir (an antiviral treatment)
  • baloxavir (an antiviral treatment)
  • low dose corticosteroids

For patients with pneumonia caused by other organisms (often referred to as 'community-acquired pneumonia' or CAP)

  • low dose corticosteroids

Data from the trial are regularly reviewed so that any effective treatment can be identified quickly and made available to all patients. Please see our news page for results that RECOVERY has found. The RECOVERY Trial team constantly review information on new drugs and may include promising ones in the trial in future.  

RECOVERY Protocol v27